Literature DB >> 3038319

Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.

M G Kris, R J Gralla, M T Burke, J J Fiore, D P Kelsen, L D Marks, R T Heelan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3038319

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.

Authors:  C Rose; T E Lad; L J Kilton; J Schor; S T Rosen; A H Rossof; R R Blough; C M Johnson
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; M L Berman
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

3.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; E Yordan; J Beecham
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.